2.4. Response evaluation and follow‐up

Treatment response was assessed every 6–8 weeks with magnetic resonance imaging (MRI) or computed tomography according to response evaluation criteria in solid tumors (RECIST version 1.1). ¹⁶ In this study, we investigated ORR, disease control rate (DCR), median progression‐free survival (PFS), and toxicities. The ORR is the proportion of patients who have a complete response (CR) or partial response (PR) to therapy, and DCR is ORR plus the proportion of patients with stable disease. Adverse events were evaluated during follow‐up and for 30 days after the last treatment. All treatment‐related toxicities were assessed according to the Common Toxicity Criteria for Adverse Events version 4.03.